XML 37 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Corrections to Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Collaborative agreement, description     Company discovered that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement: 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016).      
Due to related party $ 953,000   $ 953,000   $ 6,500,000  
Total Liabilities 1,056,130   1,056,130   6,556,470  
Additional paid-in capital 10,586,464   10,586,464   4,733,461  
Accumulated deficit (11,848,288)   (11,848,288)   (11,323,401)  
Total equity (deficit) (1,048,077)   (1,048,077)   (6,379,118)  
Selling, general and administrative expenses 169,427 $ 289,098 562,930 $ 349,486    
Research and development expenses 17,500 67,848 10,000,000    
Net loss from operations (99,479) (289,098) (476,706) (10,349,518)    
Loss from continuing operations before income taxes (127,879) (292,401) (524,057) (10,352,769)    
Net loss from continuing operations $ (127,879) $ (293,237) $ (524,887) $ (10,353,605)    
Basic and diluted loss per share $ (0.00) $ (0.00) $ (0.00) $ (0.05)    
Net loss from continuing operations $ (127,879) $ (293,237) $ (524,887) $ (10,353,605)    
Issuance of common stocks for compensation          
(Decrease) increase in due to related party     (647,000) 6,477,483    
Net cash used in operating activities     $ (1,115,484) (3,263,340)    
Previously Reported on Form 10K [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party      
Total Liabilities         56,470  
Additional paid-in capital         4,733,401  
Accumulated deficit   (669,207)   (669,207) (4,823,401)  
Total equity (deficit)         120,882  
Selling, general and administrative expenses         4,497,263  
Research and development expenses        
Net loss from operations         (4,497,295)  
Loss from continuing operations before income taxes         (4,506,963)  
Net loss from continuing operations       $ (353,605) $ (4,507,799)  
Basic and diluted loss per share       $ 0  
Net loss from continuing operations       $ (353,605) $ (4,507,799)  
Issuance of common stocks for compensation         1,295,324  
(Decrease) increase in due to related party       (22,517) (22,517)  
Net cash used in operating activities       (3,857,447)   $ (517)
Adjustments No.1 [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party   6,500,000   6,500,000 6,500,000  
Total Liabilities         6,500,000  
Additional paid-in capital          
Accumulated deficit   (10,000,000)   (10,000,000) (6,500,000)  
Total equity (deficit)         (6,500,000)  
Selling, general and administrative expenses         (3,500,060)  
Research and development expenses       10,000,000 10,000,000  
Net loss from operations         (6,499,940)  
Loss from continuing operations before income taxes         (6,499,940)  
Net loss from continuing operations       $ (10,000,000) $ (6,499,940)  
Basic and diluted loss per share       $ (0.05) $ (0.06)  
Net loss from continuing operations       $ (10,000,000) $ (6,499,940)  
Issuance of common stocks for compensation         (60)  
(Decrease) increase in due to related party       6,500,000 6,500,000  
Net cash used in operating activities       594,107  
Adjustments No.2 [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party          
Total Liabilities          
Additional paid-in capital         60  
Accumulated deficit          
Total equity (deficit)          
Selling, general and administrative expenses         60  
Research and development expenses          
Net loss from operations         (60)  
Loss from continuing operations before income taxes         (60)  
Net loss from continuing operations         $ (60)  
Basic and diluted loss per share         $ 0  
Net loss from continuing operations         $ (60)  
Issuance of common stocks for compensation         60  
(Decrease) increase in due to related party          
Net cash used in operating activities           (198)
Restated [Member]            
Corrections to Previously Issued Consolidated Financial Statements (Textual)            
Due to related party   6,500,000   6,500,000 6,500,000  
Total Liabilities         6,556,470  
Additional paid-in capital         4,733,461  
Accumulated deficit   $ (10,669,207)   (10,669,207) (11,323,401)  
Total equity (deficit)         (6,379,118)  
Selling, general and administrative expenses         997,263  
Research and development expenses       10,000,000 10,000,000  
Net loss from operations         (10,997,295)  
Loss from continuing operations before income taxes         (11,006,963)  
Net loss from continuing operations       $ (10,353,605) $ (11,007,799)  
Basic and diluted loss per share       $ (0.05) $ (0.06)  
Net loss from continuing operations       $ (10,353,605) $ (11,007,799)  
Issuance of common stocks for compensation         1,295,324  
(Decrease) increase in due to related party       6,477,483 $ 6,477,483  
Net cash used in operating activities       $ (3,263,340)   $ (715)